ESMO 2018 | Improving responses to immunotherapy in NSCLC

Victor Moreno, MD, PhD, of University Hospital Fundación Jiménez Díaz, Madrid, Spain, explores avenues for overcoming resistance to immunotherapy in cancer patients, and highlights a major advancement in precision oncology at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Dr Moreno discusses the outcomes from a recent clinical trial (NCT02383212), involving the combination of cemiplimab and radiotherapy in non-small cell lung cancer (NSCLC) patients, to demonstrate the ongoing efforts to limit resistance to immunotherapy. Dr Moreno also draws attention to a fascinating clinical trial investigating larotrectinib – a targeted therapy for patients with TRK fusions.